| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.90) per share which missed the analyst consensus estimate...
Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target...